Although fusion protein drugs do not exactly imitate PDCs since the payload is directly linked to the tumor-targeting peptide, both NGR–hTNF and tTF–NGR exhibit targeting and therapeutic characteristics identical to those of PDCs. Here, RHOH is linked to neoplasm.